Insider Buying: Sensus Healthcare (NASDAQ:SRTS) Director Acquires $112,765.25 in Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta acquired 34,697 shares of Sensus Healthcare stock in a transaction that occurred on Monday, August 24th. The shares were purchased at an average cost of $3.25 per share, for a total transaction of $112,765.25. Following the purchase, the director directly owned 209,310 shares in the company, valued at $680,257.50. The trade was a 19.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sensus Healthcare Stock Performance

NASDAQ:SRTS traded down $0.07 during trading hours on Tuesday, hitting $3.42. The stock had a trading volume of 23,189 shares, compared to its average volume of 65,146. Sensus Healthcare, Inc. has a one year low of $2.66 and a one year high of $5.49. The company has a market cap of $56.38 million, a price-to-earnings ratio of -3.64 and a beta of 1.10. The business’s 50 day moving average is $3.00 and its 200-day moving average is $3.56.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The firm had revenue of $2.29 million for the quarter, compared to the consensus estimate of $4.60 million.

Analyst Ratings Changes

SRTS has been the subject of several recent analyst reports. Lake Street Capital lowered their price target on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a report on Friday, August 14th. Weiss Ratings lowered Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Alliance Global Partners reissued a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Wall Street Zen downgraded shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Sensus Healthcare presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.83.

Institutional Trading of Sensus Healthcare

A number of institutional investors have recently modified their holdings of the company. EP Wealth Advisors LLC bought a new position in shares of Sensus Healthcare during the second quarter worth about $49,000. BlackRock Inc. bought a new stake in Sensus Healthcare in the 2nd quarter valued at approximately $252,000. Bank of New York Mellon Corp acquired a new position in Sensus Healthcare during the 2nd quarter worth approximately $303,000. North Star Investment Management Corp. acquired a new position in Sensus Healthcare during the 1st quarter worth approximately $500,000. Finally, XTX Topco Ltd bought a new position in shares of Sensus Healthcare during the 4th quarter worth approximately $77,000. 25.30% of the stock is currently owned by institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.